Platelet HMGB1 in Platelet-Rich Plasma (PRP) promotes tendon wound healing

Jianying Zhang\textsuperscript{1}, Feng Li\textsuperscript{1,2}, Tyler Augi\textsuperscript{1}, Kelly M. Williamson\textsuperscript{1}, Kentaro Onishi\textsuperscript{1,2}, MaCalus V. Hogan\textsuperscript{1,2,3}, Matthew D. Neal\textsuperscript{4}, James H.-C. Wang\textsuperscript{1,2,3,*}

\textsuperscript{1}MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, United States of America, \textsuperscript{2}Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA, United States of America, \textsuperscript{3}Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, United States of America, \textsuperscript{4}Department of Surgery, University of Pittsburgh, Pittsburgh, PA, United States of America

\textsuperscript{*}wanghc@pitt.edu

Abstract

Platelet-rich plasma (PRP) is a widely used autologous treatment for tendon injuries in clinics. Platelets (PLTs) are a major source of high mobility group box1 (HMGB1) that is gaining attention as a chemoattractant that can recruit stem cells to the wound area to enhance healing of injured tissues; however, the contribution of PLT HMGB1 in wounded tendon healing remains unexplored. This study investigated the effect of PLT HMGB1 within PRP on tendon healing using PLT HMGB1 knockout (KO) and GFP mice. A window defect was created in the patellar tendons of both groups of mice, and wounds were treated with either saline, PRP isolated from PLT HMGB1-KO mice, or PRP isolated from GFP mice. Seven days post-treatment, animals were sacrificed and analyzed by gross inspection, histology, and immunostaining for characteristic signs of tendon healing and repair. Our results showed that in comparison to mice treated with PRP from PLT HMGB1-KO mice, wounds treated with PRP from GFP mice healed faster and exhibited a better organization in tendon structure. Mice treated with PRP from PLT HMGB1-KO mice produced tendon tissue with large premature wound areas and low cell densities. However, wounds of PLT HMGB1-KO mice showed better healing with PRP from HMGB1-KO mice compared to saline treatment. Moreover, wounds treated with PRP from GFP mice had increased extracellular HMGB1, decreased CD68, increased stem cell markers CD146 and CD73, and increased collagen III protein expression levels compared to those treated with PRP from PLT HMGB1-KO mice. Thus, PLT HMGB1 within PRP plays an important role in tendon wound healing by decreasing inflammation, increasing local HMGB1 levels, and recruiting stem cells to the wound area in the tendon. Our findings also suggest that the efficacy of PRP treatment for tendon injuries in clinics may depend on PLT HMGB1 within PRP preparations.
Introduction

Tendon injuries to the Achilles and patellar tendons are prevalent in both occupational and athletics populations. Overall, healing of injured tendons is slow and yields an inferior quality of tendon tissue that is prone to re-injury. Many therapeutic approaches including injection of autologous platelet-rich plasma (PRP) have been devised to manage tendon injuries [1,2]. The use of PRP is a popular option in the treatment of tendon injuries in orthopaedics and sports medicine [1,2], however the efficacy of PRP treatment on tendon injuries, particularly in clinical trials, has been controversial. Several studies have reported that PRP can effectively treat tendon injuries [3–5], whereas others have shown the opposite with no improvement in pain or tendon function after PRP treatment [6–8]. Thus, further investigation into the role of platelets (PLTs) in tendon wound healing is essential to understand the PLT action mechanism in PRP and improve the efficacy of PRP in the treatment of tendon injuries.

Although lacking nuclei, platelets are a rich source of high mobility group box-1 (HMGB1), a highly conserved nuclear protein that is released by all cell types upon injury [9,10]. The function of HMGB1 as an inflammatory molecule or chemoattractant is dependent upon its redox state. When inside the cell, either in the nucleus or cytoplasm, HMGB1 is completely reduced as fully reduced HMGB1 (frHMGB1). Once released to the extracellular matrix, frHMGB1 is partially oxidized to disulfide HMGB1 (dsHMGB1) that is believed to initiate tissue inflammation [11]. Research has suggested that during platelet activation, HMGB1 is presented on the cell surface and released in significant amounts, with the current theory that HMGB1 is fully reduced at this stage [12–15]. Therefore, we hypothesized that platelet HMGB1 (PLT HMGB1) within PRP may have an important role in tendon injury healing. To test the hypothesis, we investigated the effect of PLT HMGB1 within PRP on wounded tendon healing using a transgenic mouse line with platelet-specific ablation of HMGB1 (PLT HMGB1-KO). The findings of this study showed that PLT HMGB1 within PRP preparations is able to promote healing and repair of tendon injuries.

Materials and methods

Animals

C57BL/6-Tg (UBC-GFP) mice (GFP mice) were obtained from Jackson Laboratory (Bar Harbor, ME). Mice with platelet-specific ablation of HMGB1 (Pf4-Cre Hmgb1<sup>fl/fl</sup> mice, referred to as PLT HMGB1-KO mice) were generated as described elsewhere using the Cre/loxP system [16].

The protocol for animal use was approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh (IACUC protocol #18083391). All experiments were performed according to the relevant guidelines and regulations. The animals were cared for by the staff of the Division of Laboratory Animal Resources (DLAR), which provides veterinarian consultation regarding animal health and welfare.

Mice were sacrificed using carbon dioxide. Secondary physical method (cervical dislocation) of euthanasia was performed to ensure death. The euthanasia method is consistent with the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. During animal experiments, no adverse events, including mortality, occurred. Only female mice were used in the experiments. For in vitro experiments, three PLT HMGB1-KO mice and three GFP mice were used. For in vivo experiments, six transgenic mice (3 PLT HMGB1-KO mice, and 3 GFP mice) were used in each of three groups (see below, Mouse tendon wound healing model). The number of mice in this study, which focused on histochemical and immunohistochemical analyses, was based on a similar, previous study [17].
**Isolation and preparation of platelets and PRP**

Mice were anesthetized with isoflurane, and blood was drawn from the retro-orbital plexus into anti-coagulated tubes. PRP was obtained by centrifugation at 500g for 10 min. Platelets were first pelleted from PRP by centrifugation at 1,000g for 10 min, and were then resuspended in ACD buffer consisting of 39 mM citric acid, 75 mM sodium citrate, and 135 mM dextrose with 5 mM of EDTA according to the published protocol [18]. This platelet solution was used for the following experiments.

**Determination of HMGB1 in activated platelets**

Isolated platelets were activated by adding 100 μl of 10,000 U/ml bovine thrombin solution into 0.4 ml of 1 × 10⁸/ml platelet-ACD solution at room temperature for 30 min. The reaction mixture was centrifuged at 1,000g for 10 min, and the supernatant was collected to determine the amount of HMGB1 released from platelets using an HMGB1 ELISA kit according to the manufacturer’s protocol (Shino-Test Corporation, Tokyo, Japan). The pellet was re-suspended with 0.9% of sodium chloride solution and reacted with a rabbit anti-mouse HMGB1 primary antibody for 3 hrs at room temperature (1:350, abcam, Cat. #ab18256), followed by a goat anti-rabbit secondary antibody conjugated with Cy3 for 1 hr at room temperature (1:500, Millipore, Cat. #AP132C).

**Mouse tendon wound healing model**

The effect of PLT HMGB1 on tendon wound healing was tested with a window defect created in each patellar tendon (PT) of PLT HMGB1-KO mice and GFP mice using a 1 mm diameter biopsy punch. Wounded PLT HMGB1-KO mice and GFP mice were divided into three groups (6 mice/group, 3 PLT HMGB1-KO mice, and 3 GFP mice). Group 1 mice were treated with 10 μl of saline (Saline), group 2 mice were treated with 8 μl of PLT HMGB1-KO PRP and 2 μl of bovine thrombin for PRP activation (KO-PRP), and group 3 mice were treated with 8 μl of GFP-PRP and 2 μl of bovine thrombin (GFP-PRP). All mice were sacrificed at 7 days post-treatment, and patellar tendons of these mice were harvested. The effect of PLT HMGB1 on wounded tendon healing and cell migration was assessed by H&E and immunostaining.

**Histochemical staining on mouse tendon tissue sections**

Tendon tissue sections were fixed with 4% paraformaldehyde for 20 min at room temperature, and then washed three times with PBS. Slides were stained with H&E at room temperature, washed with water 3 times, and dehydrated through 15%, 30%, 50%, 75%, 95% alcohol, and absolute alcohol for five minutes each. Next, slides were treated with xylene and mounted with resinous mounting medium. Finally, the staining results were observed and imaged on a microscope (Nikon eclipse, TE2000-U).

**Immunostaining on mouse tendon tissue sections**

For immunostaining, the patellar tendons were dissected from the mice and were immediately immersed in O.C.T compound (Sakura Finetek USA Inc., Torrance, CA) in disposable molds and frozen at -80°C. Then, cryo-sectioning was performed at -25°C to obtain 8 μm thick tissue sections, which were left at room temperature overnight. The tissue sections were fixed in 4% paraformaldehyde for 15 min and blocked with universal blocking solution (ThermoFisher Scientific, Pittsburgh, PA, Cat. #37515). The sections were then incubated with rabbit anti-mouse HMGB1 antibody (1:350, abcam, Cat. #ab18256) at 4°C overnight followed by goat anti-rabbit secondary antibody conjugated with Cy3 for 1 hr at room temperature (1:500,
Millipore, Cat. #AP132C). Since the purpose of this staining was to evaluate the presence of extracellular HMGB1 in the tendon, the tissue sections were not treated with the penetration reagent Triton-X100 that disrupts the nuclear membrane.

Similarly, the fixed tissue sections were reacted individually overnight at 4°C with the following primary antibodies: rabbit anti-CD68 antibody (1:500, Abcam, Cat. #125212, Cambridge, MA), rabbit anti-CD146 antibody (1:500, Abcam, Cat. #75769; Cambridge, MA), rabbit anti-CD73 antibody (1:500, LSBio, Cat. #LS-B14527-50, Seattle, WA), or rabbit anti-collagen III antibody (1:500, ThermoFisher, Cat. #22734-1-AP, Waltham, MA). In the next morning, tissue sections were washed 3 times with PBS and incubated at room temperature for 2 hrs with Cy3-conjugated goat anti-rabbit IgG antibody (1:500, Millipore, Cat. #AP132C). Total cell numbers were stained with 4’,6-diamidino-2-phenylindole (DAPI). The stained tendon tissue sections were imaged using the fluorescent microscope (Nikon eclipse, TE2000-U).

**Semi-quantification of positively stained tissue sections**

The percentage of HMGB1 expression in activated platelets from PLT HMGB1-KO and GFP mice was determined by semi-quantification. Platelets were stained for HMGB1 (as above) from three mice of each group, smeared onto a glass slide, and imaged using a fluorescent microscope (Nikon eclipse, TE2000-U). The percentages of HMGB1 expression in platelets were calculated by dividing the number of positively stained platelets with red fluorescence by the total number of platelets.

For semi-quantification of cell marker staining in tissue sections, stained tissue sections (3 sections/mouse) in each group (3 mice/group) were examined under a microscope and five random images were taken. Positively stained areas were manually identified by examining the images taken and processed using SPOT™ imaging software (Diagnostic Instruments, Inc., Sterling Heights, MI). The proportion of positive staining was calculated by dividing the positively stained area by the total area viewed under the microscope. These values were averaged to represent the percentage of positive staining in all the groups.

**Statistical analysis**

All results were obtained from 6 tendons (three mice) from each group and presented as the mean ± SD. The statistical analyses were performed with an unpaired student t-test. When \( P < 0.05 \), the two groups in comparison were considered significantly different.

**Results**

**Expression of HMGB1 is decreased in platelets of PLT HMGB1-KO mice**

First, the expression of PLT HMGB1 was assessed for both transgenic lines, specifically Pf4-Cre Hmgb1<sup>fl/fl</sup> mice, referred to as PLT HMGB1-KO mice, and GFP mice. Platelets were isolated and stained as described in the methods. Immunostaining showed that PLT HMGB1 was decreased within PLT HMGB1-KO mice (Fig 1A and 1B) compared to GFP mice (Fig 1C and 1D). Semi-quantification (Fig 1E) confirmed these results showing only ~7% of platelets in PLT HMGB1-KO mice stained positively for HMGB1, but 86% of platelets in GFP mice stained positively for HMGB1. After verifying both transgenic lines for the level of PLT HMGB1, further experiments were performed using PRP preparations to investigate the effect of PLT HMGB1 within PRP preparations on tendon wound healing.
PRP generated from PLT HMGB1-KO mice impairs tendon wound healing

Patellar tendon (PT) wounds of mice from each group were treated individually with PRP generated from either PLT HMGB1-KO mice or from GFP mice. A saline treatment was used as a control treatment. Saline treated wound exhibited large unhealed wound areas (red arrows in Fig 2A and 2D), whereas wounds treated with either KO-PRP or GFP-PRP in both mouse groups (Fig 2B, 2C, 2E and 2F) showed better healing compared to saline treated wounds. Further gross inspection showed that wound healing in the patellar tendons of PLT HMGB1-KO mice displayed greater unhealed wound areas in all treatment groups (Fig 2B and 2C, yellow and green arrow in B and C, respectively) compared to GFP mice (Fig 2E and 2F). PLT HMGB1-KO mice treated with GFP-PRP (Fig 2C) exhibited slightly better healing compared to treatment with KO-PRP (Fig 2B). However, PLT HMGB1-KO mice treated with KO-PRP (Fig 2B) had better healing than a saline treatment (Fig 2A, red arrow). These results

Fig 1. KO-PLTs contain much less HMGB1 than GFP-PLTs. A, B: HMGB1 expression in the platelets of HMGB1-KO mice (KO-PLT); C, D: HMGB1 expression in the platelets of GFP mice (GFP-PLT); B, D: Enlarged images of the box areas in the image A and C. E: Semi-quantification of positively stained platelets with HMGB1 confirms the results of immunostaining showing that only a few (~7%) platelets in HMGB1-KO mice are positively stained with HMGB1 compared to more than 86.8% of platelets in GFP mice were positively stained with HMGB1. *P < 0.01 (GFP-PLT vs. KO-PLT). Green bars: 50 μm; Yellow bars: 10 μm.

https://doi.org/10.1371/journal.pone.0251166.g001
indicated that PLT HMGB1 within PRP preparations is required for promoting tendon wound healing by PRP.

Histological analysis by H&E staining confirmed our gross inspection results. The wounds in the patellar tendons of PLT HMGB1-KO mice healed poorly overall, while wounds in GFP-PRP treated mice healed faster (Fig 3). Specifically, PLT HMGB1-KO mice treated with KO-PRP still exhibited large unhealed areas (Fig 3B, black arrow), although GFP-PRP treated

Fig 2. PRP generated from PLT HMGB1-KO mice adversely affects wounded PT healing. Results show that wounded PTs of PLT HMGB1-KO mice (KO mice) healed slower (A-C, red, yellow, and green arrows point to unhealed area) than PTs in GFP mice (D-F). However, PRP (KO-PRP or GFP-PRP) treated wound (B, C, E, F) healed much faster than the wounds treated with saline (A, D, red arrows). PT: Patellar tendon; KO-PRP: PRP prepared from PLT HMGB1-KO mice; and GFP-PRP: PRP prepared from GFP mice.

https://doi.org/10.1371/journal.pone.0251166.g002
KO mouse wound displayed better healing (Fig 3C) compared to that treated with KO-PRP (Fig 3B). In contrast, GFP-mice treated with GFP-PRP had complete healing with a normal-like tendon appearance (Fig 3F), while unhealed wound areas were found in GFP mice treated with KO-PRP (Fig 3E, black arrow). GFP-PRP treated wounds in the patellar tendon of GFP mice displayed newly formed tendon tissue in the wound area with normal-like tendon organization (Fig 3F). Saline treated tendons produced large unhealed wound areas in both mouse
groups (red arrows in Fig 3A and 3D), in contrast to PRP treatment which generally enhanced healing in patellar tendons despite the model or form of PRP used as a treatment (Fig 3B–3F). These results further confirm that PLT HMGB1 within PRP preparations is able to enhance tendon healing, and without PLT HMGB1, tendon wound healing is impaired.

HMGB1 level in tendon matrix is low in PLT HMGB1-KO mice after PRP treatment

Previous research has shown that the release of local HMGB1 from injured tissues can enhance the healing and regeneration of skeletal, hematopoietic and muscle tissues in vivo [19]. Thus, to further evaluate the role of PLT HMGB1 in PRP preparations in healing and repair, the patellar tendons from each transgenic injury model with their respective PRP treatments were evaluated for the release of tendon tissue specific HMGB1 at the site of injury. Each patellar tendon was assessed with immunostaining for HMGB1 to determine whether the presence or absence of PLT HMGB1 in both the GFP-PRP and KO-PRP may affect healing and repair within our model. Our results showed that the acute injury model induced the release of HMGB1 from local tendon tissue surrounding the wound area to the tendon matrix in both GFP mice and PLT HMGB1-KO mice, as evidenced by positively stained HMGB1 (red fluorescence in Fig 4). However, reduced levels of HMGB1 can be seen within the tendon matrix

Fig 4. HMGB1 expression in KO-PRP treated wound is much lower than GFP-PRP treated wound. Higher levels of HMGB1 are found in the wound areas of GFP tendons (M-X) than that of PLT HMGB1-KO mouse patellar tendons (A-L). GFP-PRP treated wound areas (I-L, and U-X) have much more HMGB1 than the wounds treated with saline (A-D, and M-P). KO-PRP: PRP from PLT HMGB1-KO mice; and GFP-PRP: PRP from GFP mice. Immunostaining. White bars: 200 μm; Yellow bars: 50 μm.

https://doi.org/10.1371/journal.pone.0251166.g004
of PLT HMGB1-KO mice (Fig 4A–4L) in comparison to the elevated level of HMGB1 released in tendons of GFP mice (Fig 4M–4X). Fluorescent image analysis indicated that GFP-PRP treatment increased the levels of HMGB1 in the tendon matrix of both transgenic mouse lines specifically due to treatment with GFP-PRP (Fig 4L–4L and 4U–4X). However, the concentrations of locally released HMGB1 in the tendons treated with PLT HMGB1-KO PRP were not significantly increased (Fig 4E–4H). Thus, PLT HMGB1 is able to enhance the presence of local HMGB1 at the injury site.

**PRP from PLT HMGB1-KO mice increases inflammation in wounded tendon**

Using immunostaining, collected patellar tendon tissues were analyzed for CD68, a marker of M1 pro-inflammatory macrophages [20,21]. Overall, the levels of CD68 in the wound areas of PLT HMGB1-KO mice (Fig 5A–5F) were much higher than those of GFP mice (Fig 5G–5L). Many CD68 positive cells were found in wounded tendons of both groups of mice treated with saline (Fig 5A, 5B, 5G and 5H) suggesting a high level of tissue inflammation. In PLT HMGB1-KO mice, GFP-PRP treatment decreased CD68 expression (Fig 5E and 5F) compared to PRP from KO mice (Fig 5C and 5D). However, in GFP mice, treatment with GFP-PRP significantly decreased positively stained CD68 cells (Fig 5K and 5L) compared to the same group treated with PRP from KO mice (Fig 5I and 5J). Taken together, these results suggest that ablation of PLT HMGB1 in PRP results in significant levels of CD68+ M1 macrophages in treated tendon tissues, while M1 cells are greatly reduced in tendons treated with normal PRP treatments. Semi-quantification supports these results (Fig 5M), showing that GFP-PRP is able to reduce the level of CD68+ M1 macrophages in both transgenic mouse lines, while both saline and KO-PRP are largely similar in the level of CD68+ cells.

**Stem cell marker expression is reduced in wounded mouse tendons treated with PRP from PLT HMGB1-KO**

HMGB1 have been shown to enhance tissue repair by recruiting resident stem cells [22]. Thus, to assess the effect of PLT HMGB1 on resident stem cells, patellar tendon tissues were immunostained for CD146 and CD73 stem cell marker expression [23,24]. GFP-PRP treatment of both transgenic mouse lines recruited stem cells to the wound areas, as shown by elevated CD146+ cells within GFP-PRP treated tendons (Fig 6E, 6F, 6K and 6L) compared to tendons treated with KO-PRP (Fig 6C, 6D, 6I and 6J). However, few CD146+ cells can be seen in the saline-treated tendons of PLT HMGB1-KO mice (Fig 6A and 6B) compared to saline treatment of GFP mice (Fig 6G and 6H). Overall, higher levels of CD146+ cells were found in the tendons of GFP mice (Fig 6G–6L) compared to PLT HMGB1-KO tendons (Fig 6A–6F). Semi-quantification supports these results (Fig 6M), showing that GFP-PRP treatment elevated CD146+ cells in both transgenic lines, with the highest levels found within GFP mice. Similar results were found with CD73 levels in wounded tendons (Fig 7). Few CD73+ cells can be seen within saline-treated tendons of PLT HMGB1-KO mice (Fig 7A and 7B), compared to saline treated GFP mice (Fig 7G and 7H). Overall, both PLT HMGB1-KO PRP and GFP-PRP were able to increase the level of CD73+ cells but to different degrees. GFP-PRP treatment increased CD73+ cells in both mouse lines (Fig 7E, 7F, 7K and 7L), surpassing the effect of PLT HMGB1-KO PRP on CD73 levels (Fig 7C, 7D, 7I and 7J). Semi-quantification of CD73 staining supports these results (Fig 7M), with GFP-PRP treatment producing elevated CD73+ cells in both transgenic lines with the highest levels in the treated tendons of GFP mice. Taken together, these results suggest that HMGB1 ablation in PLTs can negatively affect tendon wound healing by decreasing stem cell recruitment.
PRP from PLT HMGB1-KO mice impairs collagen III production in wounded tendons

Collagen type III (Col III) has an important role in the healing and repair of wounded tendons [25]. Immunostaining for Col III was carried out to assess healing within wounded and treated patellar tendons. Overall, Col III expression was higher in the treated tendons of GFP mice (Fig 8G–8L) compared to tendons in PLT HMGB1-KO mice (Fig 8A–8F). GFP-PRP treated wound areas (E, F, and K, L) have decreased CD68 expression compared with saline treated wounds (A, B, and G, H). Semi-quantification (M) confirms the results. *P < 0.01 (KO-PRP vs. GFP-PRP). KO-PRP: PRP from PLT HMGB1-KO mouse; and GFP-PRP: PRP from GFP mice. Immunostaining. White bars: 200 μm; Yellow bars: 50 μm.

https://doi.org/10.1371/journal.pone.0251166.g005

PRP from PLT HMGB1-KO mice impairs collagen III production in wounded tendons

Collagen type III (Col III) has an important role in the healing and repair of wounded tendons [25]. Immunostaining for Col III was carried out to assess healing within wounded and treated patellar tendons. Overall, Col III expression was higher in the treated tendons of GFP mice (Fig 8G–8L) compared to tendons in PLT HMGB1-KO mice (Fig 8A–8F). Also, GFP-PRP treatment increased Col III levels in wounded tendons in both mouse lines (Fig 8E, 8F, 8K and 8L), compared to PLT HMGB1-KO PRP treatment (Fig 8C, 8D, 8I and 8J). The results indicate that in contrast to normal PLTs in GFP mice, HMGB1-ablated PLTs impair tendon wound healing due to decreased Col III levels. Semi-quantification supports this conclusion (Fig 8M), with the GFP-PRP treatment surpassing the KO-PRP treatment in Col III.
production. Finally, similar to other results above, GFP-PRP treatment was able to produce the highest Col III production in GFP mice.

**Discussion**

This study investigated the effect of platelet-derived HMGB1 in PRP on wounded tendon healing using a transgenic mouse line with a specific platelet HMGB1 ablation. Our results demonstrated that in an acute patellar tendon injury model treated with PRP from mice lacking platelet-derived HMGB1, tendon healing was impaired. Impaired tendon healing was characterized by a decrease in local HMGB1 release from injured tissues, an increase in CD68$^+$ M1 macrophage cells, a decrease in CD146$^+$ and CD73$^+$ stem cells, and a decrease in Col III content. In contrast, treatment with PRP from GFP-mice increased local HMGB1 concentrations

Fig 6. Stem cell marker CD146 expression is much lower in KO-PRP treated wound than GFP-PRP treated wound. Very low levels of CD146 are found in the wound areas of KO-PRP treated mice (A-F) compared GFP tendons which have much higher level of CD146 expression (G-L). GFP-PRP treated wound areas (E, F, and K, L) have much more CD146 than the wounds treated with saline (A-D, and G-J). Semi-quantification (M) confirms the results. *P < 0.01 (KO-PRP vs. GFP-PRP). KO-PRP: PRP from PLT HMGB1-KO mice; and GFP-PRP: PRP from GFP mice. Immunostaining. White bars: 200 μm; Yellow bars: 50 μm.

https://doi.org/10.1371/journal.pone.0251166.g006
in the wound area, reduced the recruitment of inflammatory cells to wounded tendons, increased the recruitment of stem cells, and increased Col III levels. Although the wounds treated with PLT HMGB1-KO PRP healed faster than the wounds treated with saline, they healed much slower in comparison to wounds treated with GFP-PRP. This slowed healing is likely due to the ablation of PLT HMGB1 in these mice, with our results showing the expression of minimal amounts of PLT HMGB1 (Fig 1) that may still facilitate some level of healing compared to the saline treatment. Our results also demonstrated that GFP-PRP treatment enhanced wounded tendon healing in both mouse lines, however to a greater extent in GFP mice than in PLT HMGB1-KO mice. In GFP mice, endogenous HMGB1 in addition to PLT HMGB1 within GFP-PRP were likely collectively involved in enhancing tendon healing. Thus, our results showed that HMGB1 in platelets is a critical factor in PRP treatment, and the
efficacy of PRP treatment for tendon injuries in clinics may depend on the level of PLT HMGB1 within PRP preparations.

Tendon injury is one of the most common musculoskeletal injuries that can persist for years with poorly repaired tendon leading to further re-injury. In current clinical practices, PRP is widely used to treat tendon injuries [2,26], with a number of studies showing that PRP treatment promotes the healing and physical function of wounded tendon [1,2,5,27]. These beneficial effects are attributed to the platelets in PRP, the role of which is well-established in wound healing and tissue repair [28]. In fact, platelets are the “first responders” during wound- ing that trigger platelet activation and aggregation [29]. Once activated, platelets release many factors (e.g. cytokine and growth factors) to enhance healing of injured tissues [30].

Fig 8. Tendon matrix marker collagen III expression is much lower in KO-PRP treated wound than GFP-PRP treated wound. Very low levels of collagen III (Col III) are found in the wound areas of KO-PRP mouse patellar tendons (A-F) compared to GFP tendons with higher levels of Col III (G-L). KO-PRP and GFP-PRP treated wound areas (C-F, and I-L) have more Col III than the wounds treated with saline (A, B, and G, H). Semi-quantification (M) confirms the results. * P< 0.01 when KO-PRP treatment is compared to GFP-PRP treatment. KO-PRP: PRP from PLT HMGB1-KO mice; GFP-PRP: PRP from GFP mice. Col III: Collagen type III. Immunostaining. White bars: 200 μm; Yellow bars: 50 μm.

https://doi.org/10.1371/journal.pone.0251166.g008
In particular, HMGB1, which is abundant in platelets [13,15,31], is also released by activated platelets. It has been shown that HMGB1 released by injured tissues promotes tissue repair by inducing migration and proliferation of stem cells [32–34]. Locally released HMGB1 recruits bone marrow-derived mesenchymal stem cells (MSCs), and promotes the proliferation and differentiation of tissue-associated resident stem cells [11,34,35]. For instance, vascularization of regenerating tissue is compromised in the absence of leukocyte HMGB1 in a mouse model lacking HMGB1 in the hematopoietic system, but vessel number and vascular area were significantly higher in the presence of leukocyte HMGB1 [36]. This study indicated that leukocyte HMGB1 controls the nutrient and oxygen supply to the regenerating tissue. A study demonstrating the role of HMGB1 in muscle regeneration has shown that heterozygous HMGB1\(^{+/−}\) mice, which express 50% less HMGB1 when compared with wild type mice, have delayed muscle regeneration after acute injury [37]. Fully reduced frHMGB1 has been gaining much attention as a chemoattractant that orchestrates tissue regeneration [19,22]. This subsequent increase in stem cells in response to HMGB1 administration suggested that the regenerative properties of HMGB1 were mediated by muscle stem cells and high expression of HMGB1 is required for optimal skeletal muscle regeneration [22]. Exogenous administration of a single dose of HMGB1, either locally or systemically, promoted tissue repair by targeting endogenous stem cells. Using HMGB1\(^{+/−}\) mice, they identified the underlying mechanism as the transition of quiescent stem cells from G\(_0\) to G\(_{\text{Alert}}\), and these primed cells rapidly respond to appropriate activating factors released upon injury. These studies support our findings by highlighting the role of HMGB1 as a chemoattractant that promotes regeneration of wounded tendons by recruiting stem cells to injury site.

Macrophages are known to play an essential role in orchestrating inflammation and tissue repair [38]. Macrophages secrete various growth factors and signaling molecules and are thus involved in the regulation of inflammation, wound healing, and tissue repair [39]. Our findings show that active inflammation is present within wounds treated with PRP from PLT HMGB1-KO mice as indicated by the presence of CD68\(^+\) M1 macrophages [40], in contrast those treated with PRP from GFP mice. Inflammation can have a detrimental effect on healing. Chronic wounds fail to heal because they are stalled in an early inflammatory state during wound healing [41]. For acute injuries, prolonged inflammation can lead to slow healing which may cause the wound to enter a chronic state and fail to heal [42]. Thus, controlling inflammation may be an important step in preventing certain acute injuries from progressing to a chronic state. Research has shown that HMGB1 is able to mediate macrophage polarization [43]. M1 macrophages are characterized by a proinflammatory phenotype which produces proinflammatory cytokines, phagocytosis of microbes, and initiate an immune response [20]. M2 phenotype macrophages are a tissue-healing phenotype that releases more HMGB1, which may activate stem cells and promote tissue healing [44,45]. The switch from a proinflammatory M1 to a tissue-healing M2 phenotype in macrophages is an essential step in muscle regeneration to limit the inflammatory response [21,46]. Our results have shown that local HMGB1 is released in high levels in the wounded tendon matrix when treated with PRP from GFP mice as opposed to low levels of local HMGB1 release due to treatment with KO-PRP. This elevated level of local HMGB1 expression may help switch M1 macrophages to tissue healing M2 phenotype that may enhance healing [47]. Further research however is needed to evaluate the effect of PLT HMGB1 on the M2 phenotype and on macrophage polarization in an acute tendon injury model.

As described above, many studies have demonstrated that HMGB1 activates endogenous stem cells to accelerate tissue regeneration [19,22]. Our results indicated that tendon wounds treated with PRP from mice lacking platelet-derived HMGB1 harbor a reduced number of CD146\(^{+}\) and CD73\(^{+}\) stem cells (Figs 6 and 7). Our results indicate that both platelet and local
HMGB1 facilitates stem cell migration in normal wound healing. Our results also demonstrate high level of Col III expression in wounds treated by “regular PRP” (GFP-PRP) suggesting “normal” wound healing was occurring, in contrast to the low level in KO mice PRP treated ones. Although Col III is not a major component of the normal tendon, it is believed to play an important role during the healing process because of its ability to form rapid crosslinks and stabilize the repair site [25].

There are certain limitations with this study. As our resource for PLT HMGB1-KO mice is limited, our study only evaluated healing and repair at a single, relatively short time point (or 7 days post-injury) and only focused on the assessment of a limited number of cell markers. Further research is needed within a longer healing timeframe to further assess the effect of the ablation of PLT HMGB1 on tendon healing and repair.

In conclusion, this study has demonstrated that PLT HMGB1 within PRP plays an important role in healing wounded tendon by decreasing inflammation, increasing local HMGB1 levels, and recruiting stem cells to the wound area. These results provide the first evidence for the role of PLT HMGB1 within PRP as a therapeutic treatment to promote tendon wound healing. Our findings suggest that the efficacy of PRP treatment for tendon injuries in clinics may depend on PLT HMGB1 within PRP preparations.

Acknowledgments

We thank Dr. Bhavani P Thampatty for assistance in the preparation of this manuscript.

Author Contributions

Conceptualization: Kentaro Onishi, James H.-C. Wang.

Data curation: Jianying Zhang.

Formal analysis: Jianying Zhang, Feng Li, Tyler Augi, Kelly M. Williamson, Kentaro Onishi, Macalus V. Hogan, James H.-C. Wang.

Funding acquisition: James H.-C. Wang.

Investigation: Jianying Zhang.

Project administration: James H.-C. Wang.

Resources: Matthew D. Neal.

Supervision: James H.-C. Wang.

Visualization: Jianying Zhang.

Writing – original draft: Jianying Zhang, Kelly M. Williamson.

Writing – review & editing: James H.-C. Wang.

References

1. Andia I, Sanchez M, Maffulli N. Tendon healing and platelet-rich plasma therapies. Expert Opin Biol Ther. 2010; 10(10):1415–26. Epub 2010/08/20. https://doi.org/10.1517/14712598.2010.514603 PMID: 20718690.

2. Andia I, Martin JI, Maffulli N. Advances with platelet rich plasma therapies for tendon regeneration. Expert Opin Biol Ther. 2018:1–10. https://doi.org/10.1080/14712598.2018.1424626 PMID: 29300106.

3. Kon E, Filardo G, Di Martino A, Maracci M. Platelet-rich plasma (PRP) to treat sports injuries: evidence to support its use. Knee Surg Sports Traumatol Arthrosc. 2011; 19(4):516–27. Epub 2010/11/18. https://doi.org/10.1007/s00167-010-1306-y PMID: 21082164.
Platelet HMGB1 promotes tendon healing

4. Monto RR. Platelet rich plasma treatment for chronic Achilles tendinosis. Foot Ankle Int. 2012; 33 (5):379–85. Epub 2012/06/28. https://doi.org/10.1177/1071100712446207.

5. Dragoo JL, Wasterlain AS, Braun HJ, Nead KT. Platelet-rich plasma as a treatment for patellar tendinopathy: a double-blind, randomized controlled trial. Am J Sports Med. 2014; 42(3):610–8. Epub 2014/02/01. https://doi.org/10.1177/0278333X13518416 PMID: 24481828.

6. de Vos RJ, Weir A, van Schie HT, Bierva-Zeinsstra SM, Verhaar JA, Weimans H, et al. Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA: the journal of the American Medical Association. 2010; 303(2):144–9. Epub 2010/01/14. https://doi.org/10.1001/jama.2009.1986 PMID: 20068208.

7. de Jonge S, de Vos RJ, Weir A, van Schie HT, Bierva-Zeinsstra SM, Verhaar JA, et al. One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: a double-blind randomized placebo-controlled trial. Am J Sports Med. 2011; 39(8):1623–9. Epub 2011/05/24. https://doi.org/10.1177/0005109811404877 PMID: 21602565.

8. Schepul T, Kvist J, Norman H, Trinks M, Berlin G, Aspengren P. Autologous platelets have no effect on the healing of human achilles tendon ruptures: a randomized single-blind study. Am J Sports Med. 2011; 39(1):38–47. Epub 2010/11/06. https://doi.org/10.1177/0005109810383515 PMID: 21051425.

9. Scaffidi P, Mistelli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002; 418(6894):191–5. Epub 2002/07/12. https://doi.org/10.1038/ nature00858 PMID: 12110890.

10. Andersson U, Rauvala H. Introduction: HMGB1 in inflammation and innate immunity. J Intern Med. 2011; 270(4):296–300. Epub 2011/07/29. https://doi.org/10.1111/j.1365-2994.2011.02430.x PMID: 21793949.

11. Venereau E, Ceriotti C, Bianchi ME. DAMPs from Cell Death to New Life. Frontiers in immunology. 2015; 6:422. Epub 2015/09/09. https://doi.org/10.3389/fimmu.2015.00422 PMID: 26347745; PubMed Central PMCID: PMC4539554.

12. Maugeri N, Franchini S, Campana L, Baldini M, Ramirez GA, Sabbadini MG, et al. Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity. 2012; 45(8):584–7. Epub 2012/08/30. https://doi.org/10.3109/08916934.2012.719946 PMID: 22928592.

13. Rouhianen A, Imai S, Rauvala H, Parkkinen J. Occurrence of amphioterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost. 2000; 94(6):1087–94. Epub 2001/01/12. PMID: 11154118.

14. Vogel S, Chatterjee M, Metzger K, Borst O, Geisler T, Seizer P, et al. Activated platelets interfere with recruitment of mesenchymal stem cells to apoptotic cardiac cells via high mobility group box 1/Toll-like receptor 4-mediated down-regulation of hepatocyte growth factor receptor MET. J Biol Chem. 2014; 289(16):11068–82. Epub 2014/02/26. https://doi.org/10.1074/jbc.M113.530287 PMID: 24567326; PubMed Central PMCID: PMC4036247.

15. Stark K, Philipp V, Stockhausen S, Busse J, Antonelli A, Miller M, et al. Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. Blood. 2016; 128(20):2435. https://doi.org/10.1182/blood-2016-04-710632 PMID: 27574188.

16. Vogel S, Bodenstein R, Chen Q, Feil S, Feil R, Rheinlaender J, et al. Platelet-derived HMGB1 is a critical mediator of thrombosis. The Journal of clinical investigation. 2015; 125(12):4638–54. https://doi.org/10.1172/JCI81660 PMID: 26551681; PubMed Central PMCID: PMC4665785.

17. Zhou Y, Zhang J, Yang J, Narava M, Zhao G, Yuan T, et al. Kartogenin with PRP promotes the formation of fibrocartilage zone in the tendon-bone interface. J Tissue Eng Regen Med. 2017; 11(12):3445–56. Epub 2017/01/28. https://doi.org/10.1002/term.2258 PMID: 28127950.

18. Mardente S, Mari E, Massimi I, Tafani M, Guerriero R, Morsilli O, et al. From Human Megakaryocytes to Platelets: Effects of Aspirin on High-Mobility Group Box 1/Receptor for Advanced Glycation End Products Axis. Frontiers in immunology. 2017; 8:1946. https://doi.org/10.3389/fimmu.2017.01946 PMID: 29375570; PubMed Central PMCID: PMC5770369.

19. Lee G, Espirito Santo AT, Zwingenberger S, Cai L, Vogl T, Feldmann M, et al. Fully reduced HMGB1 accelerates the regeneration of multiple tissues by transitioning stem cells to GAlert. Proceedings of the National Academy of Sciences of the United States of America. 2018; 115(19):E4463–E72. https://doi.org/10.1073/pnas.1802893115 PMID: 29674451; PubMed Central PMCID: PMC5949009.

20. Barros MH, Hauck F, Dreyer JH, Kempkes B, Niedobitek G. Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One. 2013; 8(11):e80908. Epub 2013/11/22. https://doi.org/10.1371/journal.pone.0080908 PMID: 24260507; PubMed Central PMCID: PMC3829941.

21. Wang H, Melton DW, Porter L, Sarwar ZU, McManus LM, Shireman PK. Altered macrophage phenotype transition impairs skeletal muscle regeneration. Am J Pathol. 2014; 184(4):1167–84. Epub 2014/
22. Tirone M, Tran NL, Ceriotti C, Gorzanelli A, Canepari M, Bottinelli R, et al. High mobility group box 1 orchestrates tissue regeneration via CXCR4. The Journal of experimental medicine. 2018; 215(1):303–18. https://doi.org/10.1084/jem.20160217 PMID: 29203538; PubMed Central PMCID: PMC5748844.

23. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315–7. Epub 2006/08/23. https://doi.org/10.1080/14653260600855905 PMID: 16923606.

24. Lv FJ, Tuan RS, Cheung KM, Leung YY. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem cells (Dayton, Ohio). 2014; 32(6):1408–19. Epub 2014/03/01. https://doi.org/10.1002/stem.1681 PMID: 24578244.

25. Lui SH, Yang RS, al-Shaikh R, Lane JM. Collagen in tendon, ligament, and bone healing. A current review. Clin Orthop Relat Res. 1995;(318):265–78. Epub 1995/09/01. PMID: 7671527.

26. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009; 37(11):2259–72. https://doi.org/10.1177/0363546509349921 PMID: 19875361.

27. Kon E, Filardo G, Delcogliano M, Presti ML, Russo A, Bondi A, et al. Platelet-rich plasma: new clinical application: a pilot study for treatment of jumper's knee. Injury. 2009; 40(6):598–603. Epub 2009/04/22. https://doi.org/10.1016/j.injury.2008.11.026 PMID: 19380129.

28. Menter DG, Kopetz S, Hawk E, Sood AK, Gresele P, et al. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev. 2017; 36(2):199–213. Epub 2017/07/22. https://doi.org/10.1007/s1055-017-9682-0 PMID: 28730545; PubMed Central PMCID: PMC5709140.

29. Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev. 2014; 33(1):231–69. Epub 2014/04/04. https://doi.org/10.1007/s1055-014-9498-0 PMID: 24696047; PubMed Central PMCID: PMC4186918.

30. Eisinger F, Patzelt J, Langer HF. The Platelet Response to Tissue Injury. Front Med (Lausanne). 2018; 5:317. Epub 2018/11/30. https://doi.org/10.3389/fmed.2018.00317 PMID: 30483508; PubMed Central PMCID: PMC6242949.

31. Maugeri N, Campana L, Gavina M, Covino C, De Metrio M, Panciroli C, et al. Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. Journal of Thrombosis and Haemostasis. 2014; 12(12):2074–88. https://doi.org/10.1111/j.12710 PMID: 25163512.

32. Palumbo R, Bianchi ME. High mobility group box 1 protein, a cue for stem cell recruitment. Biochemical pharmacology. 2004; 68(6):1165–70. https://doi.org/10.1016/j.bcp.2004.03.048 PMID: 15313414.

33. Chavakis E, Hain A, Vinci M, Carmona G, Bianchi ME, Vajkoczy P, et al. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circulation research. 2007; 100(2):204–12. Epub 2007/01/16. https://doi.org/10.1161/01.RES.0000257774.55970.f4 PMID: 17218606.

34. Tamai K, Yamazaki T, Chino T, Ishii M, Otsuru S, Kikuchi Y, et al. PDGFalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(16):6609–14. Epub 2011/04/06. https://doi.org/10.1073/pnas.1016753108 PMID: 21464317; PubMed Central PMCID: PMC3681004.

35. Zhang X, Jiang H, Gong Q, Fan C, Huang Y, Ling J. Expression of high mobility group box 1 in inflamed dental pulp and its chemotactic effect on dental pulp cells. Biochem Biophys Res Commun. 2014; 450(4):1547–52. Epub 2014/07/16. https://doi.org/10.1016/j.bbrc.2014.07.027 PMID: 25019990.

36. Lampana L, Santarella F, Esposito A, Maugeri N, Rigamonti E, Monno A, et al. Leukocyte HMGB1 is required for vessel remodeling in regenerating muscles. J Immunol. 2014; 192(11):5257–64. Epub 2014/07/22. https://doi.org/10.1073/pnas.1318055111 PMID: 25019990.

37. Dromoy-Raclet V, Cammas A, Celona B, Lian XJ, van der Giessen K, Zivojnovic M, et al. HuR and miR-1192 regulate myogenesis by modulating the translation of HMGB1 mRNA. Nat Commun. 2013; 4:2388. Epub 2013/09/06. https://doi.org/10.1038/ncomms3388 PMID: 24005720; PubMed Central PMCID: PMC4005793.

38. Oishi Y, Manabe I. Macrophages in inflammation, repair and regeneration. Int Immunol. 2018; 30(11):511–28. Epub 2018/08/31. https://doi.org/10.1093/intimm/dxy054 PMID: 30165385.

39. Baum CL, Arpey CJ. Normal cutaneous wound healing: clinical correlation with cellular and molecular events. Dermatol Surg. 2005; 31(6):674–86; discussion 86. Epub 2005/07/06. https://doi.org/10.1111/j.1524-4725.2005.31612 PMID: 15996419.
40. Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood. 1993; 81(6):1607–13. Epub 1993/03/15. PMID: 7680921.

41. Zhao R, Liang H, Clarke E, Jackson C, Xue M. Inflammation in Chronic Wounds. International journal of molecular sciences. 2016; 17(12). https://doi.org/10.3390/ijms17122085 PMID: 27973441; PubMed Central PMCID: PMC5187885.

42. Serra MB, Barroso WA, da Silva NN, Silva SDN, Borges ACR, Abreu IC, et al. From Inflammation to Current and Alternative Therapies Involved in Wound Healing. International journal of inflammation. 2017; 2017:3406215. https://doi.org/10.1155/2017/3406215 PMID: 28811953; PubMed Central PMCID: PMC5547704.

43. Son M, Porat A, He M, Suurmond J, Santiago-Schwarz F, Andersson U, et al. C1q and HMGB1 reciprocally regulate human macrophage polarization. Blood. 2016; 128(18):2218–28. Epub 2016/11/05. https://doi.org/10.1182/blood-2016-05-719757 PMID: 27683415; PubMed Central PMCID: PMC5095756.

44. Bianchi ME, Crippa MP, Manfredi AA, Mezzapelle R, Rovere Querini P, Venereau E. High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair. Immunol Rev. 2017; 280(1):74–82. Epub 2017/10/14. https://doi.org/10.1111/imr.12601 PMID: 29027228.

45. Wynn TA, Vannella KM. Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity. 2016; 44(3):450–62. Epub 2016/03/18. https://doi.org/10.1016/j.immuni.2016.02.015 PMID: 26982353; PubMed Central PMCID: PMC4794754.

46. Saclier M, Cuvelier S, Magnan M, Mounier R, Chazaud B. Monocyte/macrophage interactions with myogenic precursor cells during skeletal muscle regeneration. FEBS J. 2013; 280(17):4118–30. Epub 2013/02/07. https://doi.org/10.1111/febs.12166 PMID: 23384231.

47. Roszer T. Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms. Mediators Inflamm. 2015; 2015:816460. Epub 2015/06/20. https://doi.org/10.1155/2015/816460 PMID: 26089604; PubMed Central PMCID: PMC4452191.